First Manhattan
ESPR

First Manhattan’s Esperion Therapeutics ESPR Stock Holding History

First Manhattan’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,000
Closed -$2.68K – 858
2024
Q1 		$2.68K Buy
+1,000
New +$2.43K ﹤0.01% 1263
2022
Q4 		– Sell
-340
Closed -$2K – 1721
2022
Q3 		$2K Sell
340
-70
-17% -$481 ﹤0.01% 1415
2022
Q2 		$2K Hold
410
– – ﹤0.01% 1427
2022
Q1 		$1K Hold
410
– – ﹤0.01% 1530
2021
Q4 		$2K Hold
410
– – ﹤0.01% 1470
2021
Q3 		$4K Hold
410
– – ﹤0.01% 1424
2021
Q2 		$8K Hold
410
– – ﹤0.01% 1311
2021
Q1 		$11K Hold
410
– – ﹤0.01% 1216
2020
Q4 		$10K Hold
410
– – ﹤0.01% 1145
2020
Q3 		$15K Hold
410
– – ﹤0.01% 1070
2020
Q2 		$21K Hold
410
– – ﹤0.01% 1020
2020
Q1 		$12K Buy
+410
New +$21.6K ﹤0.01% 1102

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Manhattan's ESPR Position: Q2 2024 in Review

First Manhattan sold out of Esperion Therapeutics (ESPR) in Q2 2024, closing a stake of 1,000 shares — an estimated $2.68K sold.

First Manhattan first reported a position in ESPR in Q1 2020 and held it in 12 quarters. The position peaked at $21K in Q2 2020. 176 funds tracked by Wall St. Rank hold ESPR as of Q2 2024.

  • First Manhattan reported no remaining Esperion Therapeutics position as of Q2 2024 after selling out during the quarter.
  • First Manhattan sold 1,000 Esperion Therapeutics shares in Q2 2024, an estimated $2.68K.
  • First Manhattan first reported a position in Esperion Therapeutics in Q1 2020 and held it in 12 quarters.
  • First Manhattan's Esperion Therapeutics position peaked at $21K in Q2 2020.
  • 176 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2024.

Based on First Manhattan's 13F filing for Q2 2024, filed 14 Aug 2024.